Showing results (131-140 of 196) with videos related to

Sort By:
Pageof 20
Archives of Pathology & Laboratory Medicine|November 30, 2023
Recent Advances in Genitourinary Tumors: Updates From the 5th Edition of the World Health Organization Blue Book SeriesNicole Riddle, Vinita Parkash, Charles C Guo, et al.
European Urology|October 11, 2018
Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive DiseaseRoger Li, William B Tabayoyong, Charles C Guo, et al.
The Prostate|April 2, 2011
Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profilesAna Aparicio, Vasiliki Tzelepi, John C Araujo, et al.
Cancer Cell|February 15, 2014
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapyWoonyoung Choi, Sima Porten, Seungchan Kim, et al.
Nature Communications|August 2, 2024
Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancerSakina A Plumber, Tiffany Tate, Hikmat Al-Ahmadie, et al.
Lancet (London, England)|June 28, 2016
Bladder cancerAshish M Kamat, Noah M Hahn, Jason A Efstathiou, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|January 13, 2006
Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasiaMi-Sook Kim, Joon Jeong, Tadeusz Majewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2017
Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional LandscapeZixing Wang, Tae Beom Kim, Bo Peng, et al.
Clinical Epigenetics|June 2, 2018
Urine cell-based DNA methylation classifier for monitoring bladder cancerAntoine G van der Heijden, Lourdes Mengual, Mercedes Ingelmo-Torres, et al.
European Urology Oncology|June 16, 2019
Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not BenignRoger Li, Michael J Metcalfe, William B Tabayoyong, et al.
Pageof 20